Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | CFO | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 22,438 |
Reported balance
After 2026-08-17 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-08-17 · Grant · Acquired 22,438 · Balance 22,438 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11: 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 36,459 |
Reported balance
After 2026-08-17 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-08-17 · Grant · Acquired 36,459 · Balance 36,459 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F12: 36,459 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,011 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 4,011 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F8: 4,011 restricted stock units vest on 8/15/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,089 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 23,089 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F9: 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,807 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 9,807 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F10: 4,903 restricted stock units vest on 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. |
| Common StockSEC Table I · non-derivative | Direct | 170,183 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 170,183 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.97 · Expires 2027-08-05 | Direct | 167,328 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 167,328 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.46 · Expires 2028-08-06 | Direct | 40,536 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 40,536 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 45,220 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 45,220 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 2,332 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 2,332 F1: Fully exercisable. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 45,923 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 45,923 F2: Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.91 · Expires 2034-08-15 | Direct | 32,417 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 32,417 F3: Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.60 · Expires 2035-08-15 | Direct | 37,632 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 37,632 F4: Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 24,062 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 24,062 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F6: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 29,420 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 29,420 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F7: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: Fully exercisable.
F2: Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
F3: Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
F4: Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
F6: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F7: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F8: 4,011 restricted stock units vest on 8/15/2027.
F9: 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
F10: 4,903 restricted stock units vest on 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.
F11: 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029.
F12: 36,459 restricted stock units vest on 8/17/2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 20:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 36,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000132 · form4.xml · derivative · entry 15 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,459 Underlying: Common Stock · 36,459 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F12 · derivative.exercise_date: 36,459 restricted stock units vest on 8/17/2029. F12 · derivative.expiration_date: 36,459 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 22,438 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000132 · form4.xml · derivative · entry 14 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,438 Underlying: Common Stock · 22,438 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11 · derivative.exercise_date: 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029. F11 · derivative.expiration_date: 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 4,903 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · derivative · entry 15 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,807 Underlying: Common Stock · 4,903 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11 · derivative.exercise_date: 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. F11 · derivative.expiration_date: 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 4,010 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · derivative · entry 11 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,011 Underlying: Common Stock · 4,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F7 · derivative.exercise_date: 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027. F7 · derivative.expiration_date: 4,010 restricted stock units vest on 8/15/2026; and 4,011 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerPerformance Stock Options (Right to Buy) · Derivative | 34,982 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · derivative · entry 8 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,332 Underlying: Common Stock · 34,982 shares Expires 2030-08-15 F4 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 2,332 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerPerformance Restricted Stock Units · Derivative | 12,999 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · derivative · entry 7 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,999 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · derivative · entry 6 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,999 Underlying: Common Stock · 866 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 866 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 4,310 | $72.40 | $312,044.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,183 Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 9,779 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000121 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 21:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 62,068 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0000914190-26-000108 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,068 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 21:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 51,024 | $72.03 | $3,675,258.72 |
DisclosureSEC source: 0000914190-26-000108 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,714 Read SEC document |
| July 29, 2026 Filed Jul 31, 2026 21:18 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 62,068 | $47.60 | $2,954,436.80 |
DisclosureSEC source: 0000914190-26-000108 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0000914190-26-000090 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,068 Underlying: Common Stock · 62,000 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 56,955 | $56.68 | $3,228,209.40 |
DisclosureSEC source: 0000914190-26-000090 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,670 Read SEC document |
| May 05, 2026 Filed May 7, 2026 21:26 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 62,000 | $47.60 | $2,951,200.00 |
DisclosureSEC source: 0000914190-26-000090 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:05 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0000914190-26-000080 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,068 Underlying: Common Stock · 62,000 shares Expires 2026-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:05 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 56,097 | $58.58 | $3,286,162.26 |
DisclosureSEC source: 0000914190-26-000080 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,625 Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 22:05 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 62,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000080 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 11,545 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000030 · form4.xml · derivative · entry 15 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,089 Underlying: Common Stock · 11,545 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F10 · derivative.exercise_date: 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. F10 · derivative.expiration_date: 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 13,159 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000030 · form4.xml · derivative · entry 11 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F6 · derivative.exercise_date: 13,159 restricted stock units vest on 11/1/2025. F6 · derivative.expiration_date: 13,159 restricted stock units vest on 11/1/2025. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 11,865 | $62.57 | $742,393.05 |
DisclosureSEC source: 0000914190-25-000030 · form4.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,722 Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 11,545 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000030 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 13,159 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000030 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 37,632 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · derivative · entry 17 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,632 Underlying: Common Stock · 37,632 shares Expires 2035-08-15 F13 · derivative.exercise_date: Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 14,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · derivative · entry 16 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,710 Underlying: Common Stock · 14,710 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F12 · derivative.exercise_date: 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. F12 · derivative.expiration_date: 4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 29,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · derivative · entry 15 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,420 Underlying: Common Stock · 29,420 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F11 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 4,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · derivative · entry 12 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,021 Underlying: Common Stock · 4,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F8 · derivative.exercise_date: 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027. F8 · derivative.expiration_date: 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,926 | $53.60 | $103,233.60 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,883 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:38 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 4,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014709 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,809 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 168,620 | $0.00 Strike: $44.33 | $0.00 |
DisclosureSEC source: 0001062993-25-013359 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 168,620 shares Expires 2025-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 147,431 | $58.55 | $8,632,085.05 |
DisclosureSEC source: 0001062993-25-013359 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,799 Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 20:28 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 168,620 | $44.33 | $7,474,924.60 |
DisclosureSEC source: 0001062993-25-013359 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 34,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018333 · form4.xml · derivative · entry 18 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,634 Underlying: Common Stock · 34,634 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F12 · derivative.exercise_date: 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. F12 · derivative.expiration_date: 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 13,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018333 · form4.xml · derivative · entry 14 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,159 Underlying: Common Stock · 13,159 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F8 · derivative.exercise_date: On 11/1/2024, the Board of Directors certified vesting of ____ performance RSUs. The remaining 13,159 restricted stock units vest on 11/1/2025. F8 · derivative.expiration_date: On 11/1/2024, the Board of Directors certified vesting of ____ performance RSUs. The remaining 13,159 restricted stock units vest on 11/1/2025. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 6,475 | $75.31 | $487,632.25 |
DisclosureSEC source: 0001062993-24-018333 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,610 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 13,159 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018333 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 32,417 | $0.00 Strike: $74.91 | $0.00 |
DisclosureSEC source: 0001062993-24-015387 · form4.xml · derivative · entry 16 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,417 Underlying: Common Stock · 32,417 shares Expires 2034-08-15 F11 · derivative.exercise_date: Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 12,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015387 · form4.xml · derivative · entry 15 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,031 Underlying: Common Stock · 12,031 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F10 · derivative.exercise_date: 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027. F10 · derivative.expiration_date: 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:30 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 24,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015387 · form4.xml · derivative · entry 14 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,062 Underlying: Common Stock · 24,062 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F9 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F9 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:23 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001062993-24-014510 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,867 Underlying: Common Stock · 53,000 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:23 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 36,076 | $82.35 | $2,970,858.60 |
DisclosureSEC source: 0001062993-24-014510 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,926 Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:23 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 53,000 | $31.26 | $1,656,780.00 |
DisclosureSEC source: 0001062993-24-014510 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001062993-24-014086 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,867 Underlying: Common Stock · 35,000 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 24,282 | $77.77 | $1,888,411.14 |
DisclosureSEC source: 0001062993-24-014086 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,002 Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:31 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 35,000 | $31.26 | $1,094,100.00 |
DisclosureSEC source: 0001062993-24-014086 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,284 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The Reporting Person's direct ownership has been increased by 400 shares pursuant to a clerical error in a previous filing. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionStock Options (Right to Buy) · Derivative | 47,289 | $0.00 Strike: $31.26 | $0.00 |
DisclosureSEC source: 0001062993-23-023028 · form4.xml · derivative · entry 3 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 141,867 Underlying: Common Stock · 47,289 shares Expires 2024-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 32,966 | $77.42 | $2,552,227.72 |
DisclosureSEC source: 0001062993-23-023028 · form4.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,884 Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:06 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 47,289 | $31.26 | $1,478,254.14 |
DisclosureSEC source: 0001062993-23-023028 · form4.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 26,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020119 · form4.xml · derivative · entry 16 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,318 Underlying: Common Stock · 26,318 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F10 · derivative.exercise_date: 13,159 restricted stock units vest on each of 11/1/2024 and 11/1/2025. F10 · derivative.expiration_date: 13,159 restricted stock units vest on each of 11/1/2024 and 11/1/2025. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:24 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 45,923 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016717 · form4.xml · derivative · entry 19 Hippel James · CIK 0001603594 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,923 Underlying: Common Stock · 45,923 shares Expires 2030-08-15 F10 · derivative.exercise_date: Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/27, and options to purchase 11,480 shares vest on 8/15/2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.